Why the study?
Device-related thrombus formation has emerged as a critical complication following left atrial appendage occlusion, remaining a potential limitation to its safety and efficacy.
Answers are grounded in this paper and cite their sources.
Fluoropolymer coatings on LAAO devices may improve biocompatibility and reduce the critical complication of device-related thrombus formation.
Oral anticoagulation therapy (OAC) is a mainstay for mitigating stroke and other embolic events in patients with atrial fibrillation (AF). Despite the demonstrated efficacy of OAC in reducing events, many patients are unable to tolerate OAC due to bleeding risks. Left atrial appendage occlusion (LAAO) devices were developed as implantable technologies to moderate stroke risk in patients with intolerance to OAC. Despite clinical data supporting near-comparable protection against thromboembolic events with OAC, device-related thrombus formation has emerged as a critical complication following LAAO that remains a potential limitation to the safety and efficacy of LAAO. Improved biocompatibility of LAAO devices with fluoropolymers, a well-established stent-coating technology used to reduce thrombus formation and promote endothelialization, may optimize outcomes after LAAO.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: